Effect of resilience and clinical profile in admitted to lung biopsy patients: a cross-sectional and follow-up study
Metadatos
Mostrar el registro completo del ítemAutor
HEREDIA CIURÓ, ALEJANDRO; Gámiz Molina, Ana Belén; Raya Benítez, Julia; Valenza-Peña, Geraldine; Granados Santiago, María; López López, Laura; Valenza, Marie CarmenMateria
Cancer Diagnosis Functionality Lung Biopsy Quality of Life Resilience Symptoms
Fecha
2025-07-24Referencia bibliográfica
Heredia Ciuró A, Gámiz Molina AB, Raya Benítez J, Valenza-Peña G, Granados Santiago M, López López L, Valenza MC. Effect of resilience and clinical profile in admitted to lung biopsy patients: a cross-sectional and follow-up study. Expert Rev Respir Med. 2025 Jul 24:1-8. doi: 10.1080/17476348.2025.2538277
Resumen
Background: Early diagnosis of lung cancer is crucial due to often delayed symptoms. While resilience helps patients cope with treatment, its impact on symptom severity and quality of life at diagnosis is not well understood. This study explores how resilience at diagnosis may affect clinical progression in lung cancer patients.
Research design and methods: This observational study with a 3-month follow-up included 95 patients admitted for lung biopsy. Participants were classified based on the Brief Resilience Scale (low resilience <3.00). Main variables included symptom severity, functional status, and health-related quality of life. Patients were assessed at the time of biopsy and again at 3 months.
Results: The 34.73% of patients presented low resilience and the 65.26% good resilience. Patients with low resilience presented significantly more respiratory symptoms (p<0.001), and sleep disturbances (p=0.05), added to poorer functionality and quality of life (p<0.001) than those with good resilience. Three months after the biopsy, the good resilience group kept showing lower symptom severity (p<0.05), better functionality (p<0.001) and quality of life (p<0.001) than low resilience patients.
Conclusion: Resilience appears to play a protective role in the clinical course of lung cancer and may be a valuable factor to consider in patient management strategies.




